Last updated: April 7, 2026
What is the current patent and regulatory status of Primaquine?
Primaquine is an antimalarial drug developed by GlaxoSmithKline (GSK) in the 1950s. It is a generic medication with no active patent protections in most jurisdictions, as patent protections expired decades ago. The drug is approved by the U.S. Food and Drug Administration (FDA) since 1952 and included in World Health Organization (WHO) treatment guidelines for malaria.
What is the global market size for Primaquine?
The global antimalarial drug market was valued at approximately $1.0 billion in 2022. Primaquine accounts for about 40% of this market, largely driven by its role in radical cure of Plasmodium vivax and Plasmodium ovale infections.
Specific regional contributions:
- Africa: 50%
- Southeast Asia: 25%
- Latin America: 15%
- Other: 10%
Based on these figures, the Primaquine market size in 2022 was roughly $400 million.
How do supply and demand factors influence the Primaquine market?
Demand Drivers:
- WHO guidelines recommend Primaquine for radical cure of vivax malaria.
- Increasing malaria eradication programs in endemic regions.
- Growing use in combination therapies to reduce relapse rates.
Supply Factors:
- Generic manufacturers produce Primaquine at low costs.
- Limited patent protections reduce exclusivity, increasing competition.
- Supply chain stability depends on ingredient availability and production capacity.
Market constraints:
- Potential for adverse hemolytic events in G6PD deficient individuals limits broad use.
- Regulatory policies caution against untested use without G6PD screening, affecting prescribing practices.
What are the key competitive landscape elements?
Major players:
- Generic manufacturers dominate; GSK's patent expired long ago.
- Emerging markets see increased local production, further reducing prices.
Pricing trends:
- Average wholesale price (AWP) in 2022: $0.50 per 15 mg tablet.
- Discounted prices in developing countries: $0.10–$0.20 per dose.
Market entry barriers:
- Low profit margins inhibit large brand investments.
- No new proprietary formulations or delivery methods are prominent.
What are the research and development prospects?
No recent FDA-approved new formulations or combinations specifically for Primaquine. Research focus remains on:
- Developing G6PD deficiency screening to enable safer broad deployment.
- Exploring combination regimens with other antimalarials.
- Formulation innovations to improve stability and adherence.
What is the financial outlook for Primaquine?
The market is expected to grow modestly at a compound annual growth rate (CAGR) of around 2-3% annually through 2025, primarily driven by malaria eradication programs. No significant patent-driven revenue increases are anticipated due to generic prevalence.
Factors influencing future revenue:
- Enhancements in screening methods expanding safe use.
- Increased procurement by governments for elimination efforts.
- Potential disruptions from new antimalarial therapies that might replace Primaquine in some indications.
Key regulatory considerations
- G6PD testing requirements remain critical for safe administration, influencing adoption.
- WHO prequalification status in some regions facilitates procurement.
- Regulatory delays or safety concerns could impact usage patterns.
Summary Table
| Aspect |
Details |
| Market Size (2022) |
~$400 million |
| Key Markets |
Africa (50%), Southeast Asia (25%), Latin America (15%) |
| Growth Outlook (2022-2025) |
2-3% CAGR |
| Main Drivers |
WHO guidelines, eradication programs |
| Challenges |
Safety concerns, low profitability, generic competition |
Key Takeaways
- Primaquine is a low-cost, generic antimalarial with a stable market largely driven by global health initiatives.
- Most revenues derive from endemic regions, with limited scope for patent-driven growth.
- Advances in G6PD screening are key to expanding safe use, impacting future demand.
- No significant R&D pipelines are underway for new formulations.
- Market growth remains constrained by competition and safety considerations.
FAQs
1. How does the expiration of patents affect Primaquine’s market?
Patent expiration introduced widespread generic production, reducing prices and profit margins. This limits incentives for brand-specific R&D investments.
2. What are the main safety concerns impacting Primaquine use?
Primaquine can cause hemolytic anemia in individuals with G6PD deficiency, necessitating screening before administration in many settings.
3. Are there any new formulations or delivery methods in development?
No significant proprietary formulations are in late-stage development; research focuses on diagnostics and combination therapies.
4. How does G6PD deficiency screening impact market expansion?
Screening enables broader use of Primaquine, particularly in populations previously contraindicated, potentially increasing demand.
5. What is the role of WHO in Primaquine procurement?
WHO prequalification facilitates procurement in low- and middle-income countries, supporting market stability.
Sources:
[1] World Health Organization. (2022). Guidelines for Malaria.
[2] IQVIA. (2022). Global Malaria Treatment Market Report.
[3] U.S. Food and Drug Administration. (2023). FDA Approved Drugs List.
[4] GSK. (2018). Product Information: Primaquine.
[5] Statista. (2022). Global Malaria Treatment Market Size.
